Showing results (271-280 of 410) with videos related to

Sort By:
Pageof 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaCaroline Robert, Antoni Ribas, Omid Hamid, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Melanoma Research|November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Cancer Research|February 5, 2008
Modeling genomic diversity and tumor dependency in malignant melanomaWilliam M Lin, Alissa C Baker, Rameen Beroukhim, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsF Stephen Hodi, Marcus Butler, Darryl A Oble, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 11, 2023
Profiling of Natural Killer Interactions With Cancer Cells Using Mass CytometryMargaret Hallisey, Jenna Dennis, Elizabeth P Gabriel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET)Kimberly J Perez, Nora Horick, Joanna Baginska, et al.
European Journal of Cancer (Oxford, England : 1990)|September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaOmid Hamid, Igor Puzanov, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal AntibodyNeil H Segal, Theodore F Logan, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006Omid Hamid, Caroline Robert, Adil Daud, et al.
Pageof 41